Provention Bio (PRVB)

Company Profile

Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

Company profile

Ticker

PRVB

Exchange

NASDAQ

Website

www.proventionbio.com

CEO

Ashleigh Palmer

Incorporated

Delaware

Location

New Jersey

Fiscal year end

Dec 31

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

Provention Inc.

SEC CIK

0001695357

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

PRVB stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$22.25

Low target

$18.00

High target

$30.00

Latest filings (excl ownership)

View all

8-K

Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors

Regulation FD Disclosure

3 Nov 22

Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

3 Nov 22

8-K

Entry into a Material Definitive Agreement

6 Oct 22

8-K

Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital

4 Aug 22

Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

4 Aug 22

424B3

Prospectus supplement

2 Aug 22

Transcripts

View all

PRVB

Earnings call transcript

2022 Q2

6 Aug 22

PRVB

Earnings call transcript

2022 Q1

5 May 22

PRVB

Earnings call transcript

2021 Q4

24 Feb 22

PRVB

Earnings call transcript

2021 Q3

4 Nov 21

PRVB

Earnings call transcript

2021 Q2

7 Aug 21

PRVB

Earnings call transcript

2021 Q1

8 May 21

PRVB

Earnings call transcript

2020 Q4

25 Feb 21

PRVB

Earnings call transcript

2020 Q3

7 Nov 20

PRVB

Earnings call transcript

2020 Q2

9 Aug 20

PRVB

Earnings call transcript

2020 Q1

9 May 20

Latest ownership filings

View all

Financial summary

Financial statements Chart PRVB financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	102.38 mm	102.38 mm	102.38 mm	102.38 mm	102.38 mm	102.38 mm
Cash burn (monthly)	(no burn)	3.08 mm	9.69 mm	9.49 mm	7.99 mm	7.57 mm
Cash used (since last report)	n/a	12.20 mm	38.40 mm	37.59 mm	31.65 mm	30.01 mm
Cash remaining	n/a	90.18 mm	63.98 mm	64.79 mm	70.73 mm	72.37 mm
Runway (months of cash)	n/a	29.3	6.6	6.8	8.9	9.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

PRVB institutional ownership history Ownership history

71.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	114	121	-5.8%
Opened positions	10	25	-60.0%
Closed positions	17	19	-10.5%
Increased positions	51	32	+59.4%
Reduced positions	18	28	-35.7%

13F shares	Current	Prev Q	Change
Total value	333.00 mm	183.34 mm	+81.6%
Total shares	62.23 mm	37.22 mm	+67.2%
Total puts	170.60 k	122.00 k	+39.8%
Total calls	417.30 k	338.80 k	+23.2%
Total put/call ratio	0.4	0.4	+13.5%

Largest owners	Shares	Value	Change
Sessa Capital	15.61 mm	$68.37 mm	+164.8%
Sessa Capital IM	14.88 mm	$66.96 mm	+148.0%
Adage Capital Partners GP, L.L.C.	5.77 mm	$25.97 mm	+541.1%
BLK Blackrock	5.03 mm	$22.64 mm	+9.2%
Venrock Healthcare Capital Partners II	3.84 mm	$41.05 mm	0.0%
Vanguard	3.60 mm	$16.22 mm	+39.9%
AMGN AMGEN	2.50 mm	$42.35 mm	0.0%
Geode Capital Management	1.20 mm	$5.39 mm	+25.3%
VR Adviser	1.12 mm	$5.03 mm	0.0%
Verition Fund Management	867.17 k	$3.90 mm	-9.7%

Largest transactions	Shares	Bought/sold	Change
Sessa Capital	15.61 mm	+9.71 mm	+164.8%
Sessa Capital IM	14.88 mm	+8.88 mm	+148.0%
Adage Capital Partners GP, L.L.C.	5.77 mm	+4.87 mm	+541.1%
STT State Street	0.00	-1.21 mm	EXIT
Vanguard	3.60 mm	+1.03 mm	+39.9%
BLK Blackrock	5.03 mm	+424.31 k	+9.2%
Palo Alto Investors	390.80 k	+390.80 k	NEW
Geode Capital Management	1.20 mm	+241.55 k	+25.3%
Candriam Luxembourg S.C.A.	207.65 k	+207.65 k	NEW
MPM Oncology Impact Management	740.34 k	+147.91 k	+25.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PRVB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Jan 23	Sessa Capital	Common Stock	Sell	Dispose S	No	No	9.4	3,000,000	28.20 mm	11,879,023
18 Jan 23	Francisco Leon	Common Stock	Sell	Dispose S	No	Yes	10.2679	24,015	246.58 k	1,573,000
18 Jan 23	Francisco Leon	Common Stock	Option exercise	Acquire M	No	No	2.5	24,015	60.04 k	1,597,015
18 Jan 23	Francisco Leon	Stock Option Common Stock	Option exercise	Dispose M	No	No	2.5	24,015	60.04 k	318,088
18 Jan 23	Ashleigh Palmer	Common Stock	Sell	Dispose S	No	Yes	10.2654	24,165	248.06 k	2,570,050
18 Jan 23	Ashleigh Palmer	Common Stock	Option exercise	Acquire M	No	No	2.5	24,165	60.41 k	2,594,215
18 Jan 23	Ashleigh Palmer	Stock Option Common Stock	Option exercise	Dispose M	No	No	2.5	24,165	60.41 k	517,555
17 Jan 23	Ashleigh Palmer	Stock Option Common Stock, par value $0.0001	Grant	Acquire A	No	No	10.46	700,000	7.32 mm	700,000
10 Jan 23	Thierry Chauche	Stock Option Common Stock, par value $0.0001	Grant	Acquire A	No	No	8.93	200,000	1.79 mm	200,000